Form 8-K - Current report:
SEC Accession No. 0001610618-22-000072
Filing Date
2022-09-02
Accepted
2022-09-02 17:14:41
Documents
12
Period of Report
2022-08-30
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K cdtx-20220830.htm   iXBRL 8-K 34169
  Complete submission text file 0001610618-22-000072.txt   173243

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cdtx-20220830.xsd EX-101.SCH 1897
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cdtx-20220830_lab.xml EX-101.LAB 25154
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cdtx-20220830_pre.xml EX-101.PRE 13046
6 EXTRACTED XBRL INSTANCE DOCUMENT cdtx-20220830_htm.xml XML 11290
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 221226067
SIC: 2836 Biological Products, (No Diagnostic Substances)